Zacks Investment Research upgraded shares of TOCAGEN INC (NASDAQ:TOCA) from a sell rating to a hold rating in a research note published on Tuesday.

According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

A number of other equities analysts also recently commented on the company. Stifel Nicolaus restated a buy rating and issued a $24.00 target price on shares of TOCAGEN INC in a research note on Tuesday, July 25th. Leerink Swann began coverage on TOCAGEN INC in a research note on Monday, May 15th. They issued a mkt perform rating and a $19.00 target price for the company. Finally, Evercore ISI restated an outperform rating and issued a $28.00 target price on shares of TOCAGEN INC in a research note on Tuesday, May 9th.

Shares of TOCAGEN INC (NASDAQ:TOCA) opened at 13.79 on Tuesday. The stock’s market capitalization is $273.17 million. The firm’s 50-day moving average price is $11.64 and its 200 day moving average price is $13.46. TOCAGEN INC has a 1-year low of $9.68 and a 1-year high of $17.95.

TOCAGEN INC (NASDAQ:TOCA) last issued its earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.04. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Analysts expect that TOCAGEN INC will post ($2.51) EPS for the current fiscal year.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/02/tocagen-inc-toca-rating-increased-to-hold-at-zacks-investment-research.html.

Several large investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund acquired a new stake in TOCAGEN INC during the second quarter worth $108,000. TD Asset Management Inc. acquired a new stake in TOCAGEN INC during the second quarter worth $158,000. Schwab Charles Investment Management Inc. acquired a new stake in TOCAGEN INC during the second quarter worth $165,000. California State Teachers Retirement System acquired a new stake in TOCAGEN INC during the second quarter worth $179,000. Finally, Teachers Advisors LLC acquired a new stake in TOCAGEN INC during the second quarter worth $181,000. 37.87% of the stock is currently owned by institutional investors.

TOCAGEN INC Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Get a free copy of the Zacks research report on TOCAGEN INC (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for TOCAGEN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TOCAGEN INC and related stocks with our FREE daily email newsletter.